BioCentury
ARTICLE | Clinical News

Silence golden on pancreatic cancer data

March 24, 2015 1:54 AM UTC

Silence Therapeutics plc (LSE:SLN) climbed 50.5p (21%) to 288p after preliminary Phase IIa data suggested the biotech's Atu027 had a dose-dependent effect in advanced pancreatic cancer patients.

The study included 23 patients receiving one of two dosing regimens of Atu027 plus gemcitabine over 8 weeks. Patients in the higher dose arm, who received 33% more Atu027 overall, had a median progression-free survival (PFS) of 5.3 months compared to 1.8 months in the lower dose arm. ...